Anthropic IPO will benefit these two mega-cap stocks

Anthropic confidentially filed an S-1 in June and is reportedly targeting a mid-October public listing that could rank among the year's defining IPOs. Goldman Sachs, Morgan Stanley, and JPMorgan are leading the offering, while CFO Krishna Rao has begun early investor meetings, signaling active preparation for the AI company's market debut.

Analysis

The underwriting-fee impact for GS, MS and JPM is unlikely to move FY earnings on its own; the more investable mechanism is a reopening of the growth-equity issuance window. A successful aftermarket would validate public-market appetite for cash-burning, high-capex AI platforms and could unlock a 1-3 month pipeline of AI infrastructure, cybersecurity and late-stage software issuance. MS has the cleanest second-order upside through equity-capital-markets operating leverage and wealth-management distribution; GS benefits most if the transaction stimulates sponsor and founder liquidity, while JPM is relatively less sensitive given its larger earnings base.

The key issue is valuation discipline, not deal completion. Anthropic's compute commitments and the durability of enterprise monetization will determine whether investors value it as a scarce platform or as a capital-intensive model provider; a weak aftermarket would instead widen the discount applied to late-stage AI private marks and chill adjacent IPOs. That outcome would pressure venture portfolios and reduce fee pools for the banks over the next 6-18 months, even if the transaction itself closes.

Consensus may overstate the direct bank trade: broad-bank moves ahead of marquee IPOs are often small unless issuance volumes materially follow. The cleaner expression is to own the capital-markets beta with MS versus JPM into the pricing window, then reassess after allocation demand and first-week trading establish whether this is a genuine reopening or a single-asset event. Falsify the relative thesis if MS does not outperform JPM after evidence of a broader filing calendar, or if risk appetite deteriorates through a sharp Nasdaq drawdown or higher real yields.

Key Decisions for Investors

• Initiate a 4-8 week pair: long MS / short JPM in equal dollar amounts ahead of the expected listing window. Target 3-5% relative upside if AI issuance broadens; exit on a 3% adverse relative move or evidence that the deal is delayed.
• Maintain a tactical long GS only on confirmation of a robust post-listing order book or additional large AI-related filings. The direct fee contribution is too small to justify pre-emptive size; use a 1-2 month catalyst window and cut if Nasdaq risk sentiment weakens materially.
• Monitor IPO ETF IPO and Renaissance Capital's filing calendar as confirmation indicators. A sustained rise in new filings after pricing supports adding MS and GS; a weak first-week aftermarket is a signal to avoid ECM-exposed financials.
• Do not treat this as a standalone long on GS, MS or JPM if valuation, revenue concentration, and compute-capex disclosures are unavailable before launch. Those data determine whether the offering expands the AI IPO window or resets private-market marks lower.